Wall Street brokerages expect that Aimmune Therapeutics Inc (NASDAQ:AIMT) will report earnings per share of ($0.64) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Aimmune Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.68) and the highest estimate coming in at ($0.60). Aimmune Therapeutics posted earnings per share of ($0.43) in the same quarter last year, which suggests a negative year over year growth rate of 48.8%. The firm is scheduled to report its next quarterly earnings report on Wednesday, August 9th.

According to Zacks, analysts expect that Aimmune Therapeutics will report full year earnings of ($2.58) per share for the current year, with EPS estimates ranging from ($2.69) to ($2.44). For the next year, analysts expect that the business will report earnings of ($3.24) per share, with EPS estimates ranging from ($3.37) to ($3.02). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Aimmune Therapeutics.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.05.

A number of equities research analysts have commented on the company. Zacks Investment Research lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 20th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $40.00 price target on shares of Aimmune Therapeutics in a research report on Sunday, February 19th. Finally, ValuEngine upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $33.00.

Aimmune Therapeutics (AIMT) opened at 16.47 on Monday. Aimmune Therapeutics has a 12-month low of $9.77 and a 12-month high of $27.31. The company’s market cap is $829.13 million. The company has a 50-day moving average price of $18.41 and a 200 day moving average price of $20.14.

In related news, CFO Warren L. Desouza sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 21st. The stock was sold at an average price of $22.95, for a total transaction of $229,500.00. Following the sale, the chief financial officer now owns 30,681 shares in the company, valued at approximately $704,128.95. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Warren L. Desouza sold 15,000 shares of the company’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $21.58, for a total value of $323,700.00. Following the sale, the chief financial officer now owns 35,681 shares in the company, valued at approximately $769,995.98. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,600 shares of company stock worth $565,290. 24.56% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Wellington Management Group LLP raised its stake in shares of Aimmune Therapeutics by 641.2% in the first quarter. Wellington Management Group LLP now owns 2,316,553 shares of the biotechnology company’s stock valued at $50,339,000 after buying an additional 2,004,023 shares during the last quarter. Palo Alto Investors LLC raised its stake in shares of Aimmune Therapeutics by 209.0% in the first quarter. Palo Alto Investors LLC now owns 1,173,498 shares of the biotechnology company’s stock valued at $25,500,000 after buying an additional 793,771 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Aimmune Therapeutics by 30.5% in the first quarter. Vanguard Group Inc. now owns 2,199,858 shares of the biotechnology company’s stock valued at $47,803,000 after buying an additional 513,803 shares during the last quarter. Eventide Asset Management LLC acquired a new stake in shares of Aimmune Therapeutics during the first quarter valued at approximately $6,736,000. Finally, State Street Corp raised its stake in shares of Aimmune Therapeutics by 49.1% in the first quarter. State Street Corp now owns 858,891 shares of the biotechnology company’s stock valued at $18,663,000 after buying an additional 282,744 shares during the last quarter. Institutional investors own 69.64% of the company’s stock.

WARNING: “Zacks: Analysts Expect Aimmune Therapeutics Inc (AIMT) Will Announce Earnings of -$0.64 Per Share” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/06/19/zacks-analysts-expect-aimmune-therapeutics-inc-aimt-will-announce-earnings-of-0-64-per-share.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related stocks with our FREE daily email newsletter.